Revusiran

Drug Profile

Revusiran

Alternative Names: ALN-TTRsc; SAR438714; siTTRsc

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Heart failure therapies; Small interfering RNA
  • Mechanism of Action Prealbumin inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyloid polyneuropathy; Cardiomyopathies

Most Recent Events

  • 05 Oct 2016 Discontinued - Phase-II for Amyloid polyneuropathy in Spain and Germany due to unacceptable risk benefit profile (SC)
  • 05 Oct 2016 Discontinued - Phase-III for Cardiomyopathy (In the elderly, In adults) in USA, United Kingdom, Sweden, Canada, Italy, France, Belgium, Spain and Germany due to unacceptable risk benefit profile (SC)
  • 08 Aug 2016 Alnylam Pharmaceuticals completes enrolment in the ENDEAVOUR phase III trial for Cardiomyopathy in USA, United Kingdom, Belgium, Canada, France, Germany, Italy, Sweden and Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top